152 related articles for article (PubMed ID: 913055)
1. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance.
Gibbs K; Walshe JM
Clin Sci Mol Med; 1977 Oct; 53(4):317-20. PubMed ID: 913055
[TBL] [Abstract][Full Text] [Related]
2. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
Walshe JM
QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
[TBL] [Abstract][Full Text] [Related]
3. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.
Siegemund R; Lössner J; Günther K; Kühn HJ; Bachmann H
Acta Neurol Scand; 1991 Jun; 83(6):364-6. PubMed ID: 1887758
[TBL] [Abstract][Full Text] [Related]
4. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
[TBL] [Abstract][Full Text] [Related]
5. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Purchase R
Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
[TBL] [Abstract][Full Text] [Related]
6. Triethylene-tetramine (trien) therapy for Wilson's disease.
Saito H; Watanabe K; Sahara M; Mochizuki R; Edo K; Ohyama Y
Tohoku J Exp Med; 1991 May; 164(1):29-35. PubMed ID: 1926144
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy.
McQuaid A; Mason J
J Inorg Biochem; 1991 Feb; 41(2):87-92. PubMed ID: 2033396
[TBL] [Abstract][Full Text] [Related]
8. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
Walshe JM
Q J Med; 1973 Jul; 42(167):441-52. PubMed ID: 4728043
[No Abstract] [Full Text] [Related]
9. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
10. [Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion].
Fukuoka N; Morita S; Hamatani S; Okada H; Kondoh M; Imai T; Ohnishi S; Itoh S
Yakugaku Zasshi; 2002 Aug; 122(8):585-8. PubMed ID: 12187774
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine).
Dubois RS; Rodgerson DO; Hambidge KM
J Pediatr Gastroenterol Nutr; 1990 Jan; 10(1):77-81. PubMed ID: 2324883
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents.
Brewer GJ; Yuzbasiyan-Gurkan V; Johnson V; Dick RD; Wang Y
J Am Coll Nutr; 1993 Feb; 12(1):26-30. PubMed ID: 8440814
[TBL] [Abstract][Full Text] [Related]
13. Urinary copper excretion before and after oral intake of d-penicillamine in parents of patients with Wilson's disease.
Vieira J; Oliveira PV; Juliano Y; Warde KR; Deguti MM; Barbosa ER; Carrilho FJ; Cancado EL
Dig Liver Dis; 2012 Apr; 44(4):323-7. PubMed ID: 22169274
[TBL] [Abstract][Full Text] [Related]
14. Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.
Dzieżyc K; Litwin T; Chabik G; Członkowska A
Funct Neurol; 2015; 30(4):264-8. PubMed ID: 26727705
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
Walshe JM
Lancet; 1982 Mar; 1(8273):643-7. PubMed ID: 6121964
[TBL] [Abstract][Full Text] [Related]
16. The urinary excretion of radiocopper in presymptomatic and symptomatic Wilson's disease, heterozygotes and controls: its significance in diagnosis and management.
Gibbs K; Hanka R; Walshe JM
Q J Med; 1978 Jul; 47(187):349-64. PubMed ID: 715173
[TBL] [Abstract][Full Text] [Related]
17. Comparison of disposition behavior and de-coppering effect of triethylenetetramine in animal model for Wilson's disease (Long-Evans Cinnamon rat) with normal Wistar rat.
Iseki K; Kobayashi M; Ohba A; Miyazaki K; Li Y; Togashi Y; Takeichi N
Biopharm Drug Dispos; 1992 May; 13(4):273-83. PubMed ID: 1600113
[TBL] [Abstract][Full Text] [Related]
18. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
Pfeiffenberger J; Lohse CM; Gotthardt D; Rupp C; Weiler M; Teufel U; Weiss KH; Gauss A
J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
[TBL] [Abstract][Full Text] [Related]
19. Wilson's disease.
Ala A; Walker AP; Ashkan K; Dooley JS; Schilsky ML
Lancet; 2007 Feb; 369(9559):397-408. PubMed ID: 17276780
[TBL] [Abstract][Full Text] [Related]
20. Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease.
Deguchi K; Sasaki I; Touge T; Tsukaguchi M; Ikeda K; Shimamura M; Urai Y; Watanabe S; Takeuchi H; Kuriyama S
J Neurol; 2005 Apr; 252(4):495-7. PubMed ID: 15726258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
